Department of Pharmaceuticals Discusses Biopharma Growth with Amneal Pharmaceuticals

Ahmedabad, September 16, 2026: The Department of Pharmaceuticals, Government of India, is placing greater emphasis on advanced pharmaceutical manufacturing, research and development, and biopharmaceutical innovation. As part of this broader focus, Manoj Joshi, Secretary of the Department of Pharmaceuticals, visited the corporate office of Amneal Pharmaceuticals in Ahmedabad to discuss the company’s growth plans, investments, research pipeline, and expanding capabilities. The meeting focused on India’s evolving role in the global pharmaceutical industry and the opportunities available to strengthen the country’s position in complex medicines, biosimilars, injectables, peptides, and active pharmaceutical ingredients. Amneal’s Expanding Pharmaceutical Capabilities During the visit, Amneal Pharmaceuticals presented an overview of its manufacturing infrastructure, research and development activities, global partnerships, and contribution to pharmaceutical supply chains. The company’s capabilities extend beyond conventional generic medicines and include complex formulations, injectable products, peptides, APIs, and biosimilars. Amneal’s acquisition of Kashiv BioSciences has further strengthened its position in the biopharmaceutical segment. The combination brings together Kashiv’s biologics and biosimilar expertise with Amneal’s manufacturing, commercial, and global distribution capabilities. This integration is expected to support a more connected biosimilars platform covering research, development, manufacturing, and commercialization. Biosimilars are becoming increasingly important as healthcare systems seek treatment options that may improve access and affordability while maintaining appropriate quality and regulatory standards. Focus on India’s Biopharmaceutical Future The discussion also explored how India can move from being primarily recognized for pharmaceutical manufacturing and generic medicines toward becoming a stronger hub for biopharmaceutical innovation. Several areas are important for future development, including: Greater investment in pharmaceutical research and development Advanced manufacturing infrastructure Increased innovation capital Stronger industry-academia partnerships Improved regulatory science and processes Development of skilled pharmaceutical professionals Expansion of complex medicine and biosimilar capabilities India already has a strong foundation in pharmaceutical manufacturing, but the next stage of growth may require grea…